In the LAURA Phase III trial, TAGRISSO® (osimertinib) significantly improved efficacy in treating Stage III EGFR-mutated lung cancer.
In the LAURA Phase III trial, TAGRISSO® (osimertinib) significantly improved efficacy in treating Stage III EGFR-mutated lung cancer, reducing disease progression or death risk by 84% vs. placebo. Lung cancer survival rates increased by 20% in the past five years due to advancements in screening, new drugs, and targeted therapies such as Tagrisso, Imfinzi, and Lorbrena.
June 02, 2024
5 Articles